Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

NCT06651970 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukaemia
Heart Failure

Interventions

DRUG: Acalabrutinib
OTHER: Investigator's choice of treatment

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]